Horizon Therapeutics (HZNP) Tops Q2 EPS by 74c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Horizon Therapeutics (HZNP) PT Raised to $130 at Stifel
August 4, 2021 1:16 PM EDTStifel analyst Annabel Samimy raised the price target on Horizon Therapeutics (NASDAQ: HZNP) to $130.00 (from $125.00) while maintaining a Buy rating.
The analyst commented, "With Tepezza supply resumed, we reiterate our Buy on HZNP and increase TP to $130, with demand having resumed and exceeded... More
